These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33198803)

  • 1. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
    Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
    Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
    Kim CY; Kim YC; Oh JH; Kim MH
    Anticancer Res; 2021 Jul; 41(7):3409-3417. PubMed ID: 34230136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
    Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
    Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
    Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
    Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
    Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
    Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
    Yang S; Lee JY; Hur H; Oh JH; Kim MH
    BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
    Wang L; Zhang X; Wang ZY
    Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
    Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
    Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
    BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer.
    Xie Y; Han X; Yu J; Yuan M; Yan Y; Qin J; Lan L; Wang Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18103-18117. PubMed ID: 37999751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
    Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.